Bempegaldesleukin
- Generic Name
- Bempegaldesleukin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1939126-74-5
- Unique Ingredient Identifier
- BNO1JG5MZC
- Background
Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).
- Associated Conditions
- -
- Associated Therapies
- -
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT04969861
- Locations
- 🇦🇹
Universitätsklinikum Salzburg, Landeskrankenhaus,, Salzburg, Salzburg Bundesland, Austria
🇬🇷Attikon University General Hospital, Athens, Attiki, Greece
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04646044
- Locations
- 🇺🇸
SMS Clinical Research, LLC, Mesquite, Texas, United States
🇺🇸Clinical Site Partners - Winter Park - HyperCore -PPDS, Winter Park, Florida, United States
🇺🇸A G A Clinical Trials - HyperCore - PPDS, Hialeah, Florida, United States
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT04052204
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇧🇪GZA Ziekenhuizen campus Sint-Augustinus, Wilrijk, Antwerpen, Belgium
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 41
- Registration Number
- NCT03548467
- Locations
- 🇩🇪
University Hospital Heidelberg, NCT, Im Neuenheimer Feld 460, Heidelberg, Germany
🇩🇪Universitätsmedizin Mannheim, Mannheim, Germany
🇩🇪Krankenhaus Nordwest gGmbH, Frankfurt, Germany
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT03435640
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.